SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-001747
Filing Date
2022-01-14
Accepted
2022-01-14 17:00:16
Documents
15
Period of Report
2022-01-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10032861_8k.htm   iXBRL 8-K 55976
2 EXHIBIT 3.1 brhc10032861_ex3-1.htm EX-3.1 28002
6 image00001.jpg GRAPHIC 6115
7 image00002.jpg GRAPHIC 5727
  Complete submission text file 0001140361-22-001747.txt   248206

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20220114.xsd EX-101.SCH 3935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20220114_lab.xml EX-101.LAB 23289
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20220114_pre.xml EX-101.PRE 16558
9 EXTRACTED XBRL INSTANCE DOCUMENT brhc10032861_8k_htm.xml XML 4392
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 22532505
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences